February 05, 2019
Rose
Patients suffering from a rare disorder previously were able to obtain the treatment for free from a small pharmaceutical company that offered it through an FDA program called “compassionate use.” In November, the FDA allowed Catalyst to distribute the drug, with exclusive rights to market it. The following month the company said it would sell Firdapse for $375,000 a year. In other news, lawmakers are inviting CEOs from seven major drug companies to testify on prices.
from Kaiser Health News http://bit.ly/2S98XuS
February 05, 2019
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Mystery Deepens Over Head Injuries Of U.S. Diplomats In Cuba- State Highlights: Doctor Files Whistleblower Suit Against D.C.’s Public Hospital; N.C., Minn. Officials Report Rise In Vaping Among Teens
- A Single Pharmacy In A Tiny West Virginia Town Was Shipped 12.3 Million Doses Of Opioids Over 8-Year Period
- Flashy Improvements Are Turning Gene-Editing Technology Into Swiss Army Knife Of Treatments
- Research Roundup: Kidney Disease; Bariatric Surgery Outcomes; Medicare Wellness Visits
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment